Search results for " FIBROSIS"

showing 10 items of 490 documents

Treatment of elderly HCV patients with severe fibrosis: safety and efficacy data from RESIST-HCV, a large regional database

2016

medicine.medical_specialtyDirect Acting Antivirals (DAAs); chronic hepatitis C; cirrhosisHepatologybusiness.industrycirrhosisGastroenterologyPhysical therapyMedicinechronic hepatitis CSevere fibrosisbusinessIntensive care medicineDirect Acting Antivirals (DAAs)
researchProduct

Eustachian tube dysfunction in OSMF- often present seldom discovered

2014

Objectives: To evaluate the effect of OSMF on the eustachian tube function and to correlate it with various grades of the disease. Study Design: Twenty OSMF patients (40 ears) and 20 healthy controls (40 ears) were evaluated for eustachian tube function by eustachian tube function test, tympanometry and audiometry. Results: The audiometric and tympanometric analysis showed no significant differences in hearing abilities of OSMF patients and controls and between various grades of OSMF, indicating no hearing impairment. However, eustachian tube function test revealed a statistically significant difference in eustachian tube function in OSMF patients and controls. Further, there was a signific…

medicine.medical_specialtyEustachian tubeOdontologíaAudiologyGastroenterologyInternal medicineotorhinolaryngologic diseasesmedicineDisease processGeneral DentistryOral Medicine and Pathologymedicine.diagnostic_testbusiness.industryResearchSignificant differenceEustachian tube dysfunctionTympanometry:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseCiencias de la saludConductive hearing lossmedicine.anatomical_structureOral submucous fibrosisUNESCO::CIENCIAS MÉDICASAudiometrybusinessJournal of Clinical and Experimental Dentistry
researchProduct

Fibrosis markers and CRIM1 increase in chronic heart failure of increasing severity.

2014

AbstractBackground: Fibrosis suppressors/activators in chronic heart failure (CHF) is a topic of investigation.Aim: To quantify serum levels of fibrosis regulators in CHF.Methods: ELISA tests were used to quantify fibrosis regulators, procollagen type-(PIP)I, (PIP)III, collagen-I, III, BMP1,2,3,7, SDF1α, CXCR4, fibulin 1,2,3, BMPER, CRIM1 and BAMBI in 66 CHF (NYHA class I, n = 9; II, n = 34; III n = 23), and in 14 controls.Results: In CHF, TGFβR2, PIPIII, SDF1α and CRIM1 were increased. PIPIII correlated with CRIM1.Conclusions: The BMPs inhibitor CRIM1 is increased and correlates with higher levels of serum PIPIII showing an imbalance in favor of pro-fibrotic mechanisms in CHF.

medicine.medical_specialtyHealth Toxicology and MutagenesisClinical BiochemistryInflammationBiochemistryGastroenterologySeverity of Illness IndexBone morphogenetic protein 1ElectrocardiographyFibrosisInternal medicinemedicineEndothelial dysfunction heart fibrosis inflammationHumanscardiovascular diseasesEndothelial dysfunctionHeart Failurebusiness.industryMembrane ProteinsBone Morphogenetic Protein Receptorsmedicine.diseaseFibulinProcollagen peptidaseHeart failureImmunologyChronic Diseasecardiovascular systemBAMBImedicine.symptombusinesscirculatory and respiratory physiology
researchProduct

Cardiac magnetic resonance-derived fibrosis, strain and molecular biomarkers of fibrosis in hypertensive heart disease

2020

Aims Myocardial fibrosis is a relevant component of hypertensive heart disease (HHD). Novel cardiovascular magnetic resonance (CMR) imaging techniques have shown potential in quantification of diffuse cardiac fibrosis, with T1 mapping, and estimating preclinical cardiac dysfunction, with strain analysis. Molecular biomarkers of fibrosis have been related with clinical outcomes and histologically proven myocardial fibrosis. The relationship between these CMR-imaging techniques and circulating biomarkers is not fully understood. Methods and results CMR was performed on a 3T scanner in 36 individuals with HHD. Extracellular volume fraction (ECV) and the partition coefficient were assessed usin…

medicine.medical_specialtyHeart DiseasesPhysiologyCardiac fibrosisStrain (injury)030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineFibrosisInternal medicineInternal MedicinemedicineHumans030212 general & internal medicinemedicine.diagnostic_testbusiness.industryMyocardiumHeartMagnetic resonance imagingmedicine.diseaseFibrosisMagnetic Resonance ImagingMolecular biomarkersHypertensive heart diseaseHypertensioncardiovascular systemCardiologyMyocardial fibrosisCardiology and Cardiovascular MedicineCardiac magnetic resonancebusinessJournal of Hypertension
researchProduct

Myocardial fibrosis by delayed enhancement cardiovascular magnetic resonance and HCV infection in thalassemia major patients.

2010

Abstract Abstract 4265 Introduction. Delayed enhancement (DE) cardiac magnetic resonance (CMR) technique with intravenous administration of gadolinium (Gd) chelates contrast agents is the only validated non-invasive approach for detecting myocardial fibrosis (Mahrholdt H et al, Eur Heart J 2005). This technique has been confirmed safe in patients with hemoglobinopathies (Meloni A et al, Haematologica 2009). In thalassemia major (TM), myocardial fibrosis has been detected using the DE technique and a positive correlation with anti-HCV antibodies has been described (Pepe A et al, Heart 2009). However, HCV-induced cardiomyopathy is still controversial (Matsumori A et al. J Card Fail 2006). The…

medicine.medical_specialtyHepatitis C virusThalassemiaImmunologyCardiomyopathymedicine.disease_causeBiochemistryGastroenterologyGadobutrolPathogenesisInternal medicineMyocardial fibrosisMedicinemedicine.diagnostic_testbusiness.industryMyocardial fibrosis; HCV infection; Thalassemia MajorRetrospective cohort studyMagnetic resonance imagingCell BiologyHematologymedicine.diseaseSurgeryHCV infectionMyocardial fibrosisbusinessThalassemia Majormedicine.drug
researchProduct

Effect of prevalence of liver fibrosis stages in the performance of non-invasive fibrosis biomarkers in chronic liver diseases (CLDs): Results of an …

2009

medicine.medical_specialtyHepatologyFibrosisbusiness.industryLiver fibrosisInternal medicineNon invasiveGastroenterologymedicinemedicine.diseasebusinessGastroenterologyDigestive and Liver Disease
researchProduct

Coffee and tea breaks for liver health

2017

Let food be your medicine (Hippocrates, 400 B. C.) The quality of diet, calorie intake and physical activity/sedentari-ness are pivotal drivers in the interplay between health and non-communicable diseases, and the battle against the risks associ-ated with Western-type behaviour is the top priority of medical societies and health institutions. Unfortunately, any attempt at adopting a healthy lifestyle is counteracted by unhealthy environmental pressure, which favours the diseases of affluence, including liver diseases. The typical Mediterranean diet, characterized by the consumption of complex carbohydrates, fibre-and antioxidant-rich vegetables, and polyunsaturated fatty acids, is considered…

medicine.medical_specialtyHepatologyTeabusiness.industryMEDLINEmedicine.diseaseGastroenterologyCoffeeNAFLD FIBROSIS TEA COFFEE03 medical and health sciencesElasticity Imaging Techniques0302 clinical medicineFibrosis030220 oncology & carcinogenesisInternal medicineHypertension PortalmedicineElasticity Imaging TechniquesHumans030211 gastroenterology & hepatologybusiness
researchProduct

Letter: coronary atherosclerosis in patients with significant hepatic fibrosis in non‐alcoholic fatty liver disease—the role for non‐invasive testing

2021

medicine.medical_specialtyHepatologybusiness.industryFatty liverNon invasiveGastroenterologyNon alcoholicDiseasemedicine.diseaseGastroenterologyText miningInternal medicinemedicinePharmacology (medical)In patientbusinessHepatic fibrosisCoronary atherosclerosisAlimentary Pharmacology & Therapeutics
researchProduct

Assessment by Fibroscan of fibrosis in nonalcoholic fatty liver disease: XL versus M probe?

2012

--

medicine.medical_specialtyHepatologybusiness.industryFibrosisInternal medicineNAFLD FIBROSIS FIBROSCANNonalcoholic fatty liver diseasemedicinemedicine.diseasebusinessGastroenterologyLiver pathologyHepatology
researchProduct

Efficacy and safety of Boceprevir-based therapy in HCVG1 treatment-experienced patients with advanced fibrosis/cirrhosis: Italian NPP survey

2014

S. Bruno1, S. Bollani1, A.L. Zignego2, V. Calvaruso3, C. Magni4, S. Landonio4, M. Rizzetto5, A. Ciancio5, A. Mangia6, V. Piazzolla6, M. Caremani7, S. Piovesan8, L. Cavalletto9, S. Babudieri9, A. Moretti 10, C. Colletta11, M. Massari12, S. Fangazio13, F. Mazzotta14, L. Muratori15, A.E. Colombo16, M. Zuin17, A. Traverso18, T. Santantonio19, F. Farina20, E. Marchionne21, G. Serviddio22, M. Russello23, A. Licata24, A. Craxi3, V. Di Marco3 1 Internal Medicine, AO Fatebenefratelli e Oftalmico, Milano, Italy 2 Internal Medicine, Universita di Firenze, Italy 3 Gastroenterology, Universita di Palermo, Italy 4 Infectiuos Diseases, Ospedale Sacco, Milano, Italy 5 Gastroenterology, Universita di Torino…

medicine.medical_specialtyHepatologybusiness.industryInfectious disease (medical specialty)Family medicineGastroenterologymedicinebusinessTreatment experiencedAdvanced fibrosisDigestive and Liver Disease
researchProduct